[Utilization of anti-arrhythmic drugs].
Wise utilization of antiarrhythmic drugs depends on a profound knowledge of their intracellular effects; however, due to widely varying individual response to such drugs, long clinical experience and a certain degree of empiricism are usually necessary. In view of the negatively inotropic effect of the majority of the antiarrhythmic drugs and the potential danger of their association, it seems advisable to recommend that benign arrhythmias should not be treated. Finally, a thorough understanding of the mechanism of complex arrhythmias is essential in selecting the appropriate medical treatment.
D000200:Action Potentials / Q000187:drug effects; D000404:Ajmaline / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D003327:Coronary Disease / Q000188:drug therapy; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008801:Mexiletine / Q000627:therapeutic use; D009200:Myocardial Contraction / Q000187:drug effects; D011433:Propranolol / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000188:drug therapy; D014700:Verapamil / Q000627:therapeutic use; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D000404:Ajmaline; D008801:Mexiletine; D011433:Propranolol; D014700:Verapamil
Utilisation des médicaments antiarythmiques.